Gene Expression Signatures as a Therapeutic Target for Severe H7N9 Influenza – What Do We Know So Far?

Expert Opinion on Therapeutic Targets - United Kingdom
doi 10.1517/14728222.2015.1006198
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa Healthcare

Related search

Re-Emergent Tremor: What Do We Know So Far?

Current Advances in Neurology and Neurological Disorders
2017English

Heat Shock Proteins as a Potential Therapeutic Target in the Treatment of Gestational Diabetes Mellitus: What We Know So Far

International Journal of Molecular Sciences
Organic ChemistryMolecular BiologyTheoretical ChemistryInorganic ChemistryComputer Science ApplicationsSpectroscopyMedicineCatalysisPhysical
2018English

Ketogenic Diet and Epilepsy: What We Know So Far

Frontiers in Neuroscience
Neuroscience
2019English

Trypophobia: What Do We Know So Far? A Case Report and Comprehensive Review of the Literature

Frontiers in Psychiatry
PsychiatryMental Health
2018English

What Do We Know About the Impact of AIDS on Cross-Country Income So Far?

SSRN Electronic Journal
2004English

Intrauterine Vertical Transmission of SARS-CoV-2: What We Know So Far

Ultrasound in Obstetrics and Gynecology
Nuclear MedicineRadiologyUltrasound TechnologyGynecologyReproductive MedicineRadiologicalImagingObstetricsMedicine
2020English

Clear Cell Carcinomas of the Gynecologic Tract and Thromboembolic Events: What Do We Know So Far?

Women's Health
Medicine
2014English

The Impact of Economic Crises on Social Inequalities in Health: What Do We Know So Far?

International Journal for Equity in Health
Health PolicyPublic HealthOccupational HealthEnvironmental
2014English

What Have We Learned, So Far?

Prehospital and Disaster Medicine
Emergency NursingEmergency Medicine
2002English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy